12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Ravicti glycerol phenylbutyrate regulatory update

FDA approved an NDA for Ravicti glycerol phenylbutyrate from Hyperion for the management of chronic urea cycle disorders in patients >=2 years of age. The company said it plans to launch the drug in April, but did not disclose a price for the pre-prodrug of phenylacetic acid.

In January, FDA told...

Read the full 237 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >